Paratek Pharmaceuticals Inc.

10/18/2021 | Press release | Distributed by Public on 10/18/2021 14:09

Paratek Pharmaceuticals Announces Enrollment of First Patient in Phase 2b Study Evaluating NUZYRA® (omadacycline) for Nontuberculous Mycobacterial (NTM) Pulmonary Disease[...]